Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase

Jamison Private Wealth Management, Inc. disclosed a purchase of Johnson & Johnson shares valued at $6,762,412 in its SEC filing for the period ended Q3 2025, submitted on October 14, 2025.

Increased position by 39,471 shares, with an estimated trade value of $6.76 million based on the quarter’s average price

Trade represents a 0.86% change relative to the fund’s 13F reportable assets under management

Post-trade, the fund holds 87,545 shares of Johnson & Johnson valued at $16.23 million as of September 30, 2025.

The stake now accounts for 2.06% of Jamison Private Wealth Management’s reportable AUM, which places it outside the fund's top five holdings

What happened

According to a filing with the Securities and Exchange Commission (SEC) dated October 14, 2025, Jamison Private Wealth Management, Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 39,471 shares during Q3 2025. The estimated value of shares acquired, based on the average closing price for the quarter, is $6.76 million. The fund’s total position in the company at quarter-end stood at 87,545 shares.

What else to know

This purchase brings the Johnson & Johnson stake to 2.06% of the fund’s $789.50 million reportable AUM as of September 30, 2025

Top holdings following the quarter-end are:

NASDAQ:NVDA: $35.51 million (4.5% of AUM) as of September 30, 2025

NASDAQ:AAPL: $34.23 million (4.3% of AUM) as of September 30, 2025

NASDAQ:MSFT: $33.25 million (4.2% of AUM) as of September 30, 2025

NYSE:VMC: $24.17 million (3.1% of AUM) as of September 30, 2025

NYSE:JPM: $17.55 million (2.2% of AUM) as of September 30, 2025

As of October 13, 2025, shares were priced at $190.90, up 18.1% over the past year ending October 13, 2025, outperforming the S&P 500 by 7.65 percentage points over the past year

Johnson & Johnson reported trailing twelve-month revenue of $90.63 billion and net income of $22.66 billion for the twelve months ended June 29, 2025

The stock’s annualized dividend yield stood at 2.70% as of October 14, 2025, with shares 2.86% below their 52-week high as of October 14, 2025

Company overview

Company snapshot

Offers a diversified portfolio of pharmaceuticals, and medical devices.

Generates revenue primarily through the development, manufacturing, and global sale of prescription medicines, surgical and medical devices, and over-the-counter consumer healthcare products.

Serves healthcare professionals, hospitals, wholesalers, retailers, and the general public worldwide.

Johnson & Johnson is a global healthcare leader with a broad product base spanning pharmaceuticals, MedTech, and consumer health. Its scale, established brands, and focus on research and development underpin a strong competitive position in the industry.

Foolish take

Jamison Private Wealth Management is more than a little enthusiastic about Johnson & Johnson. The pharmaceutical and medical device giant made up 2.1% of its portfolio at the end of September. At the end of June it was a 1.1% position.

Johnson & Johnson isn't a top-five holding but it's up there. It was the fund's eigth largest holding at the end of the third quarter.

Jamison's Johnson & Johnson position is working out well for the firm. The stock has more than doubled the benchmark S&P 500 index's performance this year with a gain of about 33% as of Oct. 16, 2025.

Spinning off its slow growing consumer health division in 2023 has had the intended effect on Johnson & Johnson's growth rate. Third-quarter sales rose 6.8% year over year. Encouraged by the recently strong performance, management recently raised its sales estimate for 2025 to $93.7 billion, which represents a 5.7% gain.

Glossary

AUM (Assets Under Management): The total market value of investments managed on behalf of clients by a fund or firm.
13F reportable assets: Securities that investment managers must disclose in quarterly SEC filings if they exceed $100 million in U.S. equity assets.
Dividend yield: Annual dividends per share divided by the share price, shown as a percentage.
Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.
Outperforming the S&P 500: Achieving a higher return than the S&P 500 index over a specified period.
Stake: The ownership interest or amount of shares held in a company by an investor or fund.
Quarter-end: The last day of a fiscal quarter, used as a reference point for financial reporting.
Reportable AUM: The portion of assets under management that must be disclosed in regulatory filings.
Annualized: Converted to a yearly rate based on data from a shorter period, for comparison purposes.
Top holdings: The largest investments in a fund’s portfolio, ranked by value or percentage of total assets.
MedTech: Medical technology sector, including devices, equipment, and solutions for healthcare.

JPMorgan Chase is an advertising partner of Motley Fool Money. Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, JPMorgan Chase, Microsoft, and Nvidia. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.